SG11201809672YA - Process For Preparing 5-Hydroxyalkyl-Substituted 1-Phenyl-1,2,4-Triazole Derivatives - Google Patents
Process For Preparing 5-Hydroxyalkyl-Substituted 1-Phenyl-1,2,4-Triazole DerivativesInfo
- Publication number
- SG11201809672YA SG11201809672YA SG11201809672YA SG11201809672YA SG11201809672YA SG 11201809672Y A SG11201809672Y A SG 11201809672YA SG 11201809672Y A SG11201809672Y A SG 11201809672YA SG 11201809672Y A SG11201809672Y A SG 11201809672YA SG 11201809672Y A SG11201809672Y A SG 11201809672YA
- Authority
- SG
- Singapore
- Prior art keywords
- hydroxyalkyl
- preparing
- triazole derivatives
- phenyl
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16168163 | 2016-05-03 | ||
EP16168169 | 2016-05-03 | ||
EP16168166 | 2016-05-03 | ||
EP16168172 | 2016-05-03 | ||
EP16168165 | 2016-05-03 | ||
EP17160086 | 2017-03-09 | ||
PCT/EP2017/060367 WO2017191104A1 (de) | 2016-05-03 | 2017-05-02 | Verfahren zur herstellung von 5-hydroxyalkyl-substituierten 1-phenyl-1,2,4-triazolderivativen |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809672YA true SG11201809672YA (en) | 2018-11-29 |
Family
ID=58633014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809672YA SG11201809672YA (en) | 2016-05-03 | 2017-05-02 | Process For Preparing 5-Hydroxyalkyl-Substituted 1-Phenyl-1,2,4-Triazole Derivatives |
Country Status (18)
Country | Link |
---|---|
US (2) | US10703742B2 (ko) |
EP (1) | EP3452467A1 (ko) |
JP (2) | JP6921863B2 (ko) |
KR (1) | KR20190003536A (ko) |
CN (2) | CN109071500B (ko) |
AU (2) | AU2017259872B2 (ko) |
BR (1) | BR112018072528A2 (ko) |
CA (1) | CA3022789A1 (ko) |
CL (1) | CL2018003107A1 (ko) |
CO (1) | CO2018011948A2 (ko) |
IL (1) | IL262534B (ko) |
MX (2) | MX2018013336A (ko) |
PE (1) | PE20190202A1 (ko) |
RU (1) | RU2742885C2 (ko) |
SG (1) | SG11201809672YA (ko) |
TW (1) | TWI755393B (ko) |
UY (1) | UY37222A (ko) |
WO (1) | WO2017191104A1 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10800746B2 (en) * | 2016-05-03 | 2020-10-13 | Bayer Pharma Aktiengesellschaft | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
US9988367B2 (en) * | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
CN109071500B (zh) * | 2016-05-03 | 2021-05-18 | 拜耳制药股份公司 | 制备5-羟基烷基-取代的1-苯基-1,2,4-三唑衍生物的方法 |
WO2021259852A1 (en) | 2020-06-25 | 2021-12-30 | Bayer Aktiengesellschaft | Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2038262B1 (en) * | 2006-05-25 | 2014-11-12 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
US20110237528A1 (en) * | 2008-09-19 | 2011-09-29 | Institute For Oneworld Health | Compositions and methods comprising imidazole and triazole derivatives |
DE102010001064A1 (de) * | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
LT2539326T (lt) * | 2010-02-27 | 2017-08-10 | Bayer Intellectual Property Gmbh | Sujungti bisariliniai ariltriazolonai ir jų panaudojimas |
PT2847183T (pt) * | 2012-05-08 | 2017-10-02 | Bayer Pharma AG | Processo para preparação de compostos de triazol |
JP6623220B2 (ja) * | 2014-11-03 | 2019-12-18 | バイエル ファーマ アクチエンゲゼルシャフト | ヒドロキシアルキル置換フェニルトリアゾール誘導体およびその使用 |
US10800746B2 (en) * | 2016-05-03 | 2020-10-13 | Bayer Pharma Aktiengesellschaft | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
US9988367B2 (en) * | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
CN109071500B (zh) * | 2016-05-03 | 2021-05-18 | 拜耳制药股份公司 | 制备5-羟基烷基-取代的1-苯基-1,2,4-三唑衍生物的方法 |
-
2017
- 2017-05-02 CN CN201780027607.0A patent/CN109071500B/zh not_active Expired - Fee Related
- 2017-05-02 PE PE2018002254A patent/PE20190202A1/es unknown
- 2017-05-02 MX MX2018013336A patent/MX2018013336A/es unknown
- 2017-05-02 EP EP17719636.7A patent/EP3452467A1/de not_active Withdrawn
- 2017-05-02 US US16/098,238 patent/US10703742B2/en active Active
- 2017-05-02 WO PCT/EP2017/060367 patent/WO2017191104A1/de active Application Filing
- 2017-05-02 KR KR1020187031568A patent/KR20190003536A/ko not_active Application Discontinuation
- 2017-05-02 BR BR112018072528-5A patent/BR112018072528A2/pt active Search and Examination
- 2017-05-02 SG SG11201809672YA patent/SG11201809672YA/en unknown
- 2017-05-02 AU AU2017259872A patent/AU2017259872B2/en not_active Ceased
- 2017-05-02 RU RU2018142264A patent/RU2742885C2/ru active
- 2017-05-02 CA CA3022789A patent/CA3022789A1/en active Pending
- 2017-05-02 TW TW106114435A patent/TWI755393B/zh not_active IP Right Cessation
- 2017-05-02 CN CN202110424553.XA patent/CN113105403A/zh active Pending
- 2017-05-02 UY UY0001037222A patent/UY37222A/es not_active Application Discontinuation
- 2017-05-02 JP JP2018557408A patent/JP6921863B2/ja active Active
- 2017-05-02 MX MX2020010365A patent/MX2020010365A/es unknown
-
2018
- 2018-10-23 IL IL262534A patent/IL262534B/en active IP Right Grant
- 2018-10-31 CL CL2018003107A patent/CL2018003107A1/es unknown
- 2018-11-02 CO CONC2018/0011948A patent/CO2018011948A2/es unknown
-
2020
- 2020-05-21 US US16/880,933 patent/US20200299271A1/en not_active Abandoned
-
2021
- 2021-06-14 JP JP2021098486A patent/JP2021143193A/ja not_active Withdrawn
- 2021-09-22 AU AU2021236502A patent/AU2021236502A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2021236502A1 (en) | 2021-10-21 |
EP3452467A1 (de) | 2019-03-13 |
MX2018013336A (es) | 2019-05-09 |
TWI755393B (zh) | 2022-02-21 |
IL262534A (en) | 2018-12-31 |
KR20190003536A (ko) | 2019-01-09 |
JP6921863B2 (ja) | 2021-08-18 |
TW201815782A (zh) | 2018-05-01 |
RU2018142264A3 (ko) | 2020-08-19 |
US10703742B2 (en) | 2020-07-07 |
AU2017259872A1 (en) | 2018-11-22 |
CN109071500B (zh) | 2021-05-18 |
UY37222A (es) | 2017-11-30 |
WO2017191104A1 (de) | 2017-11-09 |
US20200299271A1 (en) | 2020-09-24 |
CA3022789A1 (en) | 2017-11-09 |
RU2018142264A (ru) | 2020-06-03 |
US20190144431A1 (en) | 2019-05-16 |
JP2019514948A (ja) | 2019-06-06 |
RU2742885C2 (ru) | 2021-02-11 |
JP2021143193A (ja) | 2021-09-24 |
CN109071500A (zh) | 2018-12-21 |
AU2017259872B2 (en) | 2021-06-24 |
PE20190202A1 (es) | 2019-02-05 |
IL262534B (en) | 2021-04-29 |
CL2018003107A1 (es) | 2019-02-22 |
CO2018011948A2 (es) | 2018-11-22 |
MX2020010365A (es) | 2022-04-06 |
BR112018072528A2 (pt) | 2019-03-26 |
CN113105403A (zh) | 2021-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809672YA (en) | Process For Preparing 5-Hydroxyalkyl-Substituted 1-Phenyl-1,2,4-Triazole Derivatives | |
IL281196A (en) | Process for the preparation of methyl 6-(4,2-dichlorophenyl)-5-[4-[(S3)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-9,8-dihydro-H7-benzo[ 7]Anolene-2-carboxylate | |
MY161482A (en) | Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnapthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof | |
WO2013042138A3 (en) | Process for preparation of triazole antifungal drug, its intermediates and polymorphs thereof | |
FI119548B (fi) | Apolipoproteiini B-synteesin estäjiä | |
AR102487A1 (es) | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos | |
JP2017528504A5 (ko) | ||
JP2018519323A5 (ko) | ||
TNSN07475A1 (fr) | Arylpyrazoles substitues destines a etre utilises contre des parasites | |
NZ601316A (en) | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates | |
PH12015502088A1 (en) | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations | |
RU2501791C2 (ru) | Производное триазола или его соль | |
US20230025510A1 (en) | Biaryl ether-type quinazoline derivatives | |
JP2018511613A5 (ko) | ||
WO2007013096A8 (en) | Improved process for the preparation of 2r, 3s-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl) butan-2-ol (voriconazole) | |
JP2014501232A5 (ko) | ||
MY184577A (en) | Method for the preparation of triazole compounds | |
NI202000030A (es) | Profármacos de derivados de triazol sustituido y sus usos | |
EP0871626A1 (en) | Novel triazolones as apolipoprotein-b synthesis inhibitors | |
EP3233079A4 (en) | (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations | |
ZA202204542B (en) | Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine | |
AR076372A1 (es) | Derivados de etil-tiotriazol, composiciones farmaceuticas que los comprenden, intermediarios para su sintesis y su uso en el tratamiento de trastornos mediados por mglur5 | |
JP2017532300A5 (ko) | ||
IL249496A0 (en) | Improved process for the preparation of 4-(1-(4-(perfluoroethoxy)phenyl)-h4,2,1-1-triazol-3-yl)benzoyl azide | |
ZA202212697B (en) | Process for the preparation salts of triazole compounds |